• Skip to main content
  • Skip to footer

Qu Biologics

  • Who We Are
    • Mission and Values
    • Team and Board
  • What We Do
    • Transformational Science
    • SSI Platform
    • SSI Pipeline
    • Publications
  • Current Clinical Trials
    • RESILIENCE Study
    • PERIOP-06 Study
  • News
    • In the Press
    • Events
  • Investors
  • Careers
  • Contact
Search
Close Search

Qu Biologics RESILIENCE Study

Now Recruiting: New immunity clinical trial for adults 65 years and older

Learn More

Qu Biologics' Site Specific Immunomodulators (SSIs) are designed to restore normal immune function to treat and prevent cancer, chronic inflammatory diseases, and metabolic disease.

Learn More

Helping the Body Heal Itself

Checkerboard Transformational
Checkerboard Transformational

Transformational Science

Qu Biologics is pioneering the development of SSIs, a first-in-class immunotherapy platform. SSIs emerged from Qu’s seminal discovery that the body’s natural immune response may be harnessed and directed to specific organs. SSIs overcome immune dysfunction that underlies cancer, chronic inflammatory diseases, metabolic disease, and aging.

Learn More

Mission Statement

Qu’s mission is to transform the treatment and prevention of cancer, chronic inflammatory diseases, and metabolic disease, by restoring the full breadth of normal immune function.

Learn More

Checkerboard Mission
Checkerboard Mission
Checkerboard Trials
Checkerboard Trials

Current Clinical Trials

Qu Biologics currently has two Phase 2 randomized double-blind placebo-controlled clinical trials in progress:

Our RESILIENCE Study is designed to evaluate whether Qu’s QBKPN SSI immunomodulator can improve immune function in people 65 years of age or older, including how well it can protect against respiratory and other infections and what effect it has on maintaining or improving quality of life, activity level, and health status.

Our PERIOP-06 Study is designed to evaluate whether Qu’s QBECO SSI can prevent post-operative innate immune suppression and improve survival in people with late-stage colon cancer undergoing surgery for liver metastasis.

Learn More

Pipeline

Qu Biologics is advancing the promise of SSIs across multiple important diseases, including oncology, chronic inflammatory diseases, metabolic disease, and diseases of aging.

Learn More

Qu Biologics Pipeline
Checkerboard Pipeline

Latest News

Checkerboard Trials
10 Feb 2025
Clinical News, News, Uncategorized
Qu Biologics’ Immunomodulator Clears Senescence
More
Blog Post Placeholder Image4
06 Jan 2025
Clinical News, News, Technology News
Qu Biologics’ Immunomodulator Improves Fatty Liver Disease
More
Blog Post Placeholder Image2
16 Dec 2024
Clinical News, News, Technology News
Qu Biologics’ Site Specific Immunomodulator Enables CAR T-cell Cancer Efficacy in Solid Tumor
More

More Posts

Latest Events

Digital Sunnyside Manor Event Poster
09 Apr 2025
Events
The Important Role of Natural Immunity in Health and Aging with Dr. Hal Gunn, MD
Three Links Manor Digital Event Poster
26 Feb 2025
Events
The Important Role of Natural Immunity in Health and Aging with Dr. Hal Gunn, MD
Digital Sgsc Event Poster
21 Feb 2025
Events
The Important Role of Natural Immunity in Health and Aging with Dr. Hal Gunn, MD

More Events

join us

Careers

Join a team of innovators who have a passion to make a difference. Our ambitious team
has achieved a number of major milestones, and we have many big goals ahead.

Learn More

Logo Light
  • Who We Are
  • What We Do
  • Current Clinical Trials
  • News
  • Investors
  • Careers
  • Contact
  • 4475 Wayburne Drive, Suite 305 Burnaby, B.C., Canada, V5G 4X4
  • 604.734.1450
    info@qubiologics.com

dashicons-facebook-alt
dashicons-twitter
dashicons-linkedin
dashicons-youtube

© 2025 Qu Biologics Inc. All Rights Reserved
| Terms of Use | Privacy Policy